US EditionPublished • loading... • Updated
Obexelimab Stops New MS Brain Lesions in Clinical Trial, Data Show
Summary by Multiple Sclerosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Obexelimab shows promising results in reducing lesions in relapsing multiple sclerosis, highlighting its potential as a new treatment for autoimmune diseases.
Obexelimab stops new MS brain lesions in clinical trial, data show
Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis […] The post Obexelimab stops new MS brain lesions in clinical trial, data show appeared first on Multiple Sclerosis News Today.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
